Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Koenig

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Antimicrobial Agents and Chemotherapy|April 25, 2007
Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster modelJohn D Morrey, Venkatraman Siddharthan, Aaron L Olsen, et al.
Blood|June 8, 2006
CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphomaChristopher T Rankin, Maria-Concetta Veri, Sergey Gorlatov, et al.
Plos One|December 11, 2013
Isolation of cancer stem like cells from human adenosquamous carcinoma of the lung supports a monoclonal origin from a multipotential tissue stem cellJennie P Mather, Penelope E Roberts, Zhuangyu Pan, et al.
Blood|January 25, 2008
CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapyPing Zhou, Raymond L Comenzo, Adam B Olshen, et al.
Journal of Molecular Biology|April 13, 2010
Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletionSyd Johnson, Stephen Burke, Ling Huang, et al.
Immunology Letters|December 17, 2009
IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcgammaRIIA and FcgammaRIIBCarol T Cady, Maree S Powell, Ronald J Harbeck, et al.
Breast Cancer Research : BCR|December 2, 2011
Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding propertiesJeffrey L Nordstrom, Sergey Gorlatov, Wenjun Zhang, et al.
Science Translational Medicine|May 29, 2015
A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primatesGurunadh R Chichili, Ling Huang, Hua Li, et al.
Plos Pathogens|November 6, 2015
Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T CellsDerek D Sloan, Chia-Ying Kao Lam, Alivelu Irrinki, et al.
Arthritis and Rheumatism|May 28, 2010
Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffoldMaria-Concetta Veri, Stephen Burke, Ling Huang, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Antimicrobial Agents and Chemotherapy|April 25, 2007
Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster modelJohn D Morrey, Venkatraman Siddharthan, Aaron L Olsen, et al.
Blood|June 8, 2006
CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphomaChristopher T Rankin, Maria-Concetta Veri, Sergey Gorlatov, et al.
Plos One|December 11, 2013
Isolation of cancer stem like cells from human adenosquamous carcinoma of the lung supports a monoclonal origin from a multipotential tissue stem cellJennie P Mather, Penelope E Roberts, Zhuangyu Pan, et al.
Blood|January 25, 2008
CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapyPing Zhou, Raymond L Comenzo, Adam B Olshen, et al.
Journal of Molecular Biology|April 13, 2010
Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletionSyd Johnson, Stephen Burke, Ling Huang, et al.
Immunology Letters|December 17, 2009
IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcgammaRIIA and FcgammaRIIBCarol T Cady, Maree S Powell, Ronald J Harbeck, et al.
Breast Cancer Research : BCR|December 2, 2011
Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding propertiesJeffrey L Nordstrom, Sergey Gorlatov, Wenjun Zhang, et al.
Science Translational Medicine|May 29, 2015
A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primatesGurunadh R Chichili, Ling Huang, Hua Li, et al.
Plos Pathogens|November 6, 2015
Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T CellsDerek D Sloan, Chia-Ying Kao Lam, Alivelu Irrinki, et al.
Arthritis and Rheumatism|May 28, 2010
Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffoldMaria-Concetta Veri, Stephen Burke, Ling Huang, et al.
Pageof 6